Suchergebnisse - "Lugtenburg, Pieternella J"

PubPharm (155)

1

Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Neppelenbroek, S. | Geurts, Y. | Aleman, B. | +22

2

Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma : a contemporary, nationwide, population-based study in the Netherlands

enthalten in: Blood cancer journal | 2024

von Pennings, E. | Durmaz, M. | Visser, O. | +6

3

No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21 : a population-based study

enthalten in: Blood advances | 2023

von Geerdes, E. | Durmaz, M. | Lugtenburg, P. | +8

4

The Dutch CAR-T Tumorboard Experience : Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

enthalten in: Cancers | 2023

von Spanjaart, A. | Pennings, E. | Mutsaers, P. | +19

5

An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients

enthalten in: Scientific reports | 2023

von Ferrández, M. | Golla, S. | Eertink, J. | +31

6

Cellular therapy in lymphoma

enthalten in: Hematological oncology | 2023

von Sureda, A. | Lugtenburg, P. | Kersten, M. | +11

7

How I treat older patients with DLBCL in the frontline setting

enthalten in: Blood | 2023

von Lugtenburg, P. | Mutsaers, P.

ErratumIn: Blood. 2023 Sep 21;142(12):1103. - PMID 37733375

8

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma : Dose Expansion in a Phase I/II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Thieblemont, C. | Phillips, T. | Ghesquieres, H. | +20

CommentIn: Nat Rev Clin Oncol. 2023 Mar;20(3):138. - PMID 36646813

9

Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities

enthalten in: JCO oncology practice | 2023

von Spanjaart, A. | Pennings, E. | Kos, M. | +13

10

Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor

enthalten in: European journal of nuclear medicine and molecular imaging | 2023

von Zwezerijnen, G. | Eertink, J. | Ferrández, M. | +7

CommentOn: EJNMMI Phys. 2019 Dec 26;6(1):28. - PMID 31879795

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]